Genus

GNSHealthcare
2,095.00GBX
-0.24%
Market Cap
1.38B
Volume
67.1k
36% of avg
P/E Ratio
0.24
EPS (TTM)
86.13
Beta
0.58
Day Range
2,070.00p - 2,130.00p
52 Week Range
1,424.00p2,095.00p2,160.00p
2,095.00p

Upcoming Events

31 May 2025
Professor Jason Chin to step down from Genus Board
GNS
NEUTRAL

Genus Appoints New Financial Adviser and Joint Corporate Broker

The animal genetics company has appointed J.P. Morgan Securities plc as its new Financial Adviser and joint Corporate Broker.

GNS
NEUTRAL

Genus Receives FDA Approval for PRRS Resistant Pig

The animal genetics company has received regulatory approval for its innovative PRRS Resistant Pig product in the US market.

GNS
NEUTRAL

Genus plc Notifies Major Shareholding Change

The healthcare company has received notification of a change in major shareholdings.

GNS
NEUTRAL

Genus plc Notifies Major Shareholding Change

The healthcare company has received notification of a change in major shareholdings.

GNS
NEUTRAL

Genus Announces Director Share Dealings

The healthcare company has announced details of restricted stock awards granted to an executive, including vesting and sale of shares to cover tax liabilities.

GNS
NEUTRAL

Genus PLC Announces Change in Major Shareholder

The healthcare company has announced that BlackRock, Inc. has increased its stake in the firm to over 5% of the voting rights.

GNS
NEUTRAL

Genus Appoints New Chief Financial Officer

The healthcare company has appointed a new Chief Financial Officer to succeed the retiring incumbent.

GNS
NEUTRAL

Genus CEO Exercises Options, Retains Shares

The CEO of this major biotechnology company has exercised stock options and sold a portion of the resulting shares.

GNS
GOOD

Genus PLC Reports Strong Half-Year Performance with 19% Profit Growth

The animal genetics company reported a 19% increase in adjusted operating profit, strong cash generation, and strategic progress in key markets. Despite currency headwinds, the outlook remains positive with increased profit expectations for FY25.

GNS
NEUTRAL

Genus Announces Non-Executive Director Retirement

The animal genetics company announces the retirement of a Non-Executive Director, who is leaving to take on a new role.